Roivant Sciences Ltd. — Director's Dealing 2022

Nov 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2022-11-10

Reporting Person: Dexcel Pharma Technologies Ltd. (10% Owner)
Reporting Person: Dexxon Holdings Ltd. (10% Owner)
Reporting Person: Oren Dan (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-10	Common Shares	P	4000000	$5.00	Acquired	102849443	Direct

Footnotes

F1: Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 4,684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.

F2: The common shares were purchased by Dexcel in a registered public offering on November 10, 2022.